참고문헌
- DeFronzo R, Bonadonna R, Ferrannini E. Pathogenesis of NIDDM: a balanced overview. Diabetes Care 15:318-368, 1992 https://doi.org/10.2337/diacare.15.3.318
- DeFronzo R. Pathogenesis of type 2 diabetes; metabolic and molecular implications for identifying diabetes genes. Diabetes Reviews 5:177-269, 1997
- Weyer C, Bogardus C, Mott D, Pratley R. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999 https://doi.org/10.1172/JCI7231
- American Diabetes association. Postprandial blood glucose. Diabetes Care 24:775-778, 2001 https://doi.org/10.2337/diacare.24.4.775
- Matthai S, Stmvoll M, Kellerer M, Haring H. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21:585-618, 2000 https://doi.org/10.1210/er.21.6.585
- Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo R. The metabolic profile of NIDDM is fully established in glucosetolerant offsprings of two Mexican-American NIDDM parents. Diabetes 41:1575-1586, 1992 https://doi.org/10.2337/diabetes.41.12.1575
- Lillioja S, Mott D, Howard B, Bennett P, Yki-Jarvinen H, Freymond D, Nyomba B, Zurlo F, Swinburn B, Bogardus C. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225, 1988 https://doi.org/10.1056/NEJM198805123181901
- Martin B, Warram J, Krolewski A, Bergman R, Soeldner J, Kahn C. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929, 1992 https://doi.org/10.1016/0140-6736(92)92814-V
- Kendler B. Carnitine. An overview if its role in preventive medicine. Preventive Medicine 15:373-390, 1986 https://doi.org/10.1016/0091-7435(86)90005-8
- Rebouche C, Seim H. Carnitine metabolism and its regulation in microorganisms and mammals. Annu Rev Nutr 8:39-61, 1998
- Derosa G, Cicero A, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 25:1429-1439, 2003 https://doi.org/10.1016/S0149-2918(03)80130-3
- Brooks S, Bahl J, Bressler R. Carnitine in the streptozotocin-diabetic rat. J Nutr 115:1267-1273, 1985 https://doi.org/10.1093/jn/115.10.1267
- Giancaaterini A, De Gaetano A, Mingrone G, Capristo E, Greco A. Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism 49:704-708, 2000 https://doi.org/10.1053/meta.2000.6250
- Lowitt S, Malone J, Salem A, Korthals J, Benford S. Acetyl L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44:677-680, 1995 https://doi.org/10.1016/0026-0495(95)90128-0
- Heo Y, Lee Y, Cha Y. L-carnitine Administration Improves Lipid Metabolism in Streptozotocin-induced diabetic rat. Nutritional Science 5:3-8, 2002
- Yoshikawa Y, Ueda E, Sahurai H, Kojima Y. Anti-diabetices effect of Zn(II)/carnitine complex by oral administration. Chem Pharm Bull 51:230-231, 2003 https://doi.org/10.1248/cpb.51.230
- Reaven G. Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988 https://doi.org/10.2337/diabetes.37.12.1595
- Laakso M. Hyperglycemia and cardiovascular disease in Type 2 diabetes. Diabetes 48:937-942, 1999 https://doi.org/10.2337/diabetes.48.5.937
- Howard B. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28:613-628, 1987
- Cavallero E, Dachet C, Neufcou D, Wirquin E, Mathe D, Jacotot B. Postprandial amplication of lipopotein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagons levels. Metabolism 43:270-278, 1994 https://doi.org/10.1016/0026-0495(94)90092-2
- Niina M, Mikko S, Marja-riitta T. Postprandial lipid metabolism in diabetes. Atherosclerosis 141suppl:S53-S55, 1998 https://doi.org/10.1016/S0021-9150(98)00148-8
- Bieber L. Carnitine. AnnRev Biochem 57:261-283, 1988 https://doi.org/10.1146/annurev.bi.57.070188.001401
- Bell F, Vidmar R, Raymond T. L-carnitine administration and withdrawal affect plasma and hepatic carnitine concentrations, plasma lipid and lipoprotein composition, and in vitro hepatic lipogenesis from labeled mevalonate and olate in normal rabits. J Nutr 122:959-966, 1992 https://doi.org/10.1093/jn/122.4.959
- Monola P, Belfiore A, Santangelo F, Senicchio M. L-Carnitine on the apolipoprotein pattern of rats fed a cholesterol-rich diet. Comp Biochem Physiol 89:69-73, 1988 https://doi.org/10.1016/0305-0491(88)90263-5
- Sachan D, Dodsan W. The serum carnitine status of cancer patients. J Am Nutr 6(2):14-15, 1987